Elacestrant Shows Strong PFS Gains in Phase 2 ELEVATE Trial for Advanced ER⁺/HER2‑ Breast Cancer – SABCS 2025 Update

Why Elacestrant Is Poised to Redefine ER‑Positive Breast Cancer Treatment

Menarini Group and its subsidiary Stemline Therapeutics have just shared promising phase‑2 data from the ELEVATE trial. The study examined oral combinations of the selective estrogen receptor degrader (SERD) elacestrant with either everolimus or abemaciclib in patients whose tumors are estrogen‑receptor positive (ER+) and HER2‑negative (HER2‑). The results hint at a new standard for tackling endocrine resistance.

Key Takeaways From the ELEVATE Findings

• Consistent progression‑free survival (PFS) benefit across all ESR1‑mutation statuses.
• Elacestrant + everolimus: median PFS ≈ 8.3 months (n=50).
• Elacestrant + abemaciclib: median PFS ≈ 14.3 months (n=60).
• No new safety signals; toxicity matched the known profiles of each drug.

These numbers suggest that elacestrant can act as a robust backbone for combination regimens, especially in patients who have progressed on prior endocrine therapy with or without CDK4/6 inhibition.

Future Trends Shaping ER+/HER2‑ Breast Cancer Care

1. Oral SERDs Will Lead the Next Generation of Endocrine Therapy

Traditional oral aromatase inhibitors (AIs) are being eclipsed by SERDs that not only block the estrogen receptor but also degrade it. Elacestrant’s oral formulation removes the need for injections, positioning it favorably against emerging competitors such as giredestrant and amcenestrant.

2. Dual‑Targeted Combinations to Overcome Resistance

Combining a SERD with a PI3K/mTOR inhibitor (everolimus) or a CDK4/6 inhibitor (abemaciclib) tackles two major resistance pathways simultaneously. This “two‑pronged” approach could become the default strategy for patients who have exhausted single‑agent endocrine options.

3. Precision Medicine Guided by ESR1 Mutations

Although ELEVATE showed benefit regardless of ESR1 status, ongoing trials are stratifying patients by specific mutation types (e.g., Y537S, D538G). Tailoring therapy based on the molecular fingerprint of the tumor will sharpen efficacy and minimize unnecessary toxicity.

4. Real‑World Evidence (RWE) Will Accelerate Adoption

Registries and electronic health‑record databases are already capturing outcomes for patients on oral SERDs. Early RWE suggests comparable PFS to trial data and highlights adherence advantages of a fully oral regimen.

Real‑World Example: A Patient’s Journey With an Oral SERD

Maria, a 58‑year‑old from Texas, progressed on letrozole and a CDK4/6 inhibitor. After enrolling in a compassionate‑use program for elacestrant + abemaciclib, she achieved a 12‑month disease‑free interval, allowing her to postpone chemotherapy. Her story underscores how oral combinations can extend quality‑of‑life while maintaining disease control.

Did You Know?

Oral SERDs reduce clinic visits by up to 60% compared with injectable options, improving patient convenience and decreasing healthcare costs.

Pro Tips for Clinicians Considering Elacestrant‑Based Regimens

1. Assess prior CDK4/6 exposure: Patients naïve to CDK4/6 inhibitors may derive a larger PFS boost from the elacestrant + abemaciclib combo.
2. Monitor mTOR‑related toxicities: Keep an eye on hyperglycemia and mucositis when pairing elacestrant with everolimus.
3. Leverage genomic testing: ESR1 mutation testing can guide sequencing decisions, especially in heavily pre‑treated populations.

Related Articles You Might Find Helpful

• The Rise of SERDs: A 2024 Overview
• Choosing the Right CDK4/6 Inhibitor for ER+ Breast Cancer
• Targeting the mTOR Pathway: What Oncologists Need to Know

External Resources

• U.S. FDA – Drug Approvals
• ClinicalTrials.gov – ELEVATE Study Details
• Nature Reviews Clinical Oncology – SERD Landscape

Frequently Asked Questions

What is elacestrant?

Elacestrant is an oral selective estrogen receptor degrader (SERD) designed to destroy the estrogen receptor, thereby halting tumor growth in ER+ breast cancer.

How does elacestrant differ from traditional aromatase inhibitors?

Unlike aromatase inhibitors, which lower estrogen levels, elacestrant directly targets and degrades the receptor, offering activity against tumors that have become resistant to estrogen depletion.

Can elacestrant be used after CDK4/6 inhibitor failure?

Yes. Current data show meaningful PFS benefits when combined with a CDK4/6 inhibitor (abemaciclib) even after prior CDK4/6 exposure.

Are there any new safety concerns with these combinations?

No new safety signals have emerged; adverse events align with the known profiles of everolimus and abemaciclib.

Will oral SERDs replace injectable SERDs?

While injectable SERDs remain valuable, the convenience and adherence advantages of oral SERDs like elacestrant are driving rapid adoption in many treatment algorithms.

Take the Next Step

Are you a clinician interested in integrating elacestrant into your practice, or a patient seeking more information? Reach out to our oncology editorial team for deeper insights, or subscribe to our newsletter for the latest updates on breast‑cancer therapeutics.